Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00502866 · ClinicalTrials.gov registry record
Study to Assess the Use of a Simple Lab Test to Screen for Rickets in Children
A clinical trial, sponsored by Agency for Healthcare Research and Quality (AHRQ).
- Completed
- Registry status
- 246
- Enrollment target
NCT00502866: Completed study, sponsored by Agency for Healthcare Research and Quality (AHRQ).
NCT00502866 is a clinical trial that has completed, run by Agency for Healthcare Research and Quality (AHRQ). The registered enrollment target is 246 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00502866 has completed, sponsored by Agency for Healthcare Research and Quality (AHRQ).
- COMPLETED
- Registry status
- 246 participants
- Enrollment target
Study Summary
Some experts recommend that all breastfed babies receive supplemental vitamin D. The purpose of this study is to determine the rate of vitamin D use in breastfed babies, the recommendations of pediatricians regarding vitamin D, and the impact on these recommendations on parental choice of vitamin D. In addition, in preparation for a large study to see how many breastfed children who don't receive supplemental vitamin D have rickets, in this study we will determine if a simple blood test, an alkaline phosphatase level, could be used to screen for rickets. Parents of children 6-23 months old are eligible to complete feeding surveys and children 6-15 months old who were breastfed for at least the first six months of life and didn't routinely receive vitamin D are eligible for alkaline phosphatase levels. We postulate that most breastfed babies don't receive supplemental vitamin D, and that alkaline phosphatase levels will only be abnormal in a few babies who will have evidence on x-ray of rickets.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2006-06 |
| Est. Completion | 2008-06 |
What the finished NCT00502866 record still lists
NCT00502866 is an observational study that tracks outcomes without assigning an intervention. The registered 246 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00502866 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00502866 about?
NCT00502866 is a clinical study titled "Study to Assess the Use of a Simple Lab Test to Screen for Rickets in Children". Some experts recommend that all breastfed babies receive supplemental vitamin D. The purpose of this study is to determine the rate of vitamin D use in breastfed babies, the recommendations of pediatricians regarding vitamin D, and the impact on these recommendations on parental choice of vitamin D....
What is the current status of trial NCT00502866?
This trial is currently completed. The enrollment target is 246 participants. The study started on 2006-06. Estimated completion is 2008-06.
Who is sponsoring clinical trial NCT00502866?
This trial is sponsored by Agency for Healthcare Research and Quality (AHRQ), which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04973605 · 246 participants · Phase 1
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- NCT06395168 · 246 participants · NA
Mayo Clinic Health System Northwest Wisconsin Integrated Maternal Postpartum Appointment Combination
- NCT07048769 · 246 participants · Phase 4
Paracervical Block for Pain Reduction in Saline Infusion Sonograms
- NCT07176650 · 246 participants · Phase 1
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia